https://www.selleckchem.com/products/ctpi-2.html
Reliable quantification of dopamine transporter (DAT), a biomarker for Parkinson's disease (PD), is essential for diagnostic purposes as well as for evaluation of potential disease-modifying treatment. Due to degeneration of dopaminergic neurons and thus lower expected radioligand binding to DAT, higher measurement variability in PD patients might be expected than earlier reproducibility results in healthy controls. Therefore, we aimed to examine the test-retest properties of [ F]FE-PE2I-PET in PD patients. Nine patients with PD (Hoehn a
Like
Comment
Share
